Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018

 Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018

Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

Shots:

  • Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I), CSCC(P-I), HCC(P-I), BCC (P-II), R/M Cervical Cancer (P-I), Libtayo + RT+ GM-CSF for R/M HNSCC (P-I)
  • Libtayo is a mAb targeting the immune checkpoint receptor PD-1 and was recently approved by the US FDA to treat locally advanced CSCC or mCSCC
  • In 2015, Regeneron and Sanofi globally collaborated to develop Libtayo using Regeneron’s VelocImmune technology for treatment across various tumor types

Click here to read full press release/ article | Ref:  Regeneron | Image: Investors

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post